Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Other Operating Expenses (2023 - 2024)

Fate Therapeutics' Other Operating Expenses history spans 4 years, with the latest figure at $14.7 million for Q4 2024.

  • For Q4 2024, Other Operating Expenses changed N/A year-over-year to $14.7 million; the TTM value through Sep 2025 reached $14.7 million, changed N/A, while the annual FY2024 figure was $14.7 million, 836.85% up from the prior year.
  • Other Operating Expenses reached $14.7 million in Q4 2024 per FATE's latest filing, up from -$2.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $14.7 million in Q4 2024 to a low of -$2.0 million in Q1 2023.